TY - JOUR T1 - Pregnancy during COVID-19: social contact patterns and vaccine coverage of pregnant women from CoMix in 19 European countries JF - medRxiv DO - 10.1101/2022.06.01.22275775 SP - 2022.06.01.22275775 AU - Kerry LM Wong AU - Amy Gimma AU - Enny S Paixao AU - CoMix Europe Working Group AU - Christel Faes AU - Philippe Neutels AU - Niel Hens AU - Christopher I Jarvis AU - W. John Edmunds Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/02/2022.06.01.22275775.abstract N2 - Background Evidence and advice for pregnant women evolved during the COVID-19 pandemic. We studied social contact behaviour and vaccine uptake in pregnant women between March 2020 and September 2021 in 19 European countries.Methods In each country, repeated online survey data were collected from a panel of nationally-representative participants. We calculated the mean adjusted contacts reported with an individual-level generalized additive mixed model, modelled using the negative binomial distribution and a log link function. Mean proportion of people in isolation or quarantine, and vaccination coverage by pregnancy status and gender were calculated using a clustered bootstrap.Findings We recorded 4,129 observations from 1,041 pregnant women, and 115,359 observations from 29,860 non-pregnant individuals aged 18-49. Pregnant women made slightly fewer contacts (3.6, 95%CI=3.5-3.7) than non-pregnant women (4.0, 95%CI=3.9-4.0), driven by fewer work contacts but marginally more contacts in non-essential social settings. Approximately 15-20% pregnant and 5% of non-pregnant individuals reported to be in isolation and quarantine for large parts of the study period.COVID-19 vaccine coverage was higher in pregnant women than in non-pregnant women between January and April 2021. Since May 2021, vaccination in non-pregnant women began to increase and surpassed that in pregnant women.Interpretation Social contacts and vaccine uptake protect pregnant women and their newborn babies. Recognition of maternal social support need, and efforts to promote the safety and effectiveness of the COVID-19 vaccines during pregnancy are high priorities in this vulnerable group.Competing Interest StatementThere are no competing interests to declare.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. HPRU in Modelling & Health Economics (NIHR200908: KLMW); European Union Horizon 2020 research and innovation programme (EpiPose 101003688: AG, WJE) Wellcome Trust (213589/Z/18/Z: ESP) European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (TransMID 682540: CF, PN, NH) This research was partly funded by the Global Challenges Research Fund (GCRF) project RECAP managed through RCUK and ESRC (ES/P010873/1: CIJ) NIHR (PR_OD_1017_20002: WJE) UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: WJE) The funders had no role in study design, analysis, decision to publish or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participation in this opt-in study was voluntary, and all analyses were carried out on anonymised data. In the UK, the study was approved by the ethics committee of the London School of Hygiene and Tropical Medicine (Reference number: 21795). In Belgium, the study was approved by Ethical Comimtte of the University Hospital Antwerp. In The Netherlands, waiver was obtained from Medische Ethische Toetsingscommissie Utrecht. In Austria, the study was waived by Ethikkommission der Stadt Wien. In Denmark, waiver was obtained from The Central Denmark Region Committees on Health Research Ethics. In France, waiver was obtained from Direction centrale du renseignement interieur Centre Hospitalier Universitaire de Poitiers. In Poland, the study was approved by Komisja Bioetyczna, Narodowego Instytutu Zdrowia Publicznego, Panstwowego Zaldadu Higieny, Warszawa. In Portugal, the study was approved by Comissao de Etica para a Saude do Instituto Nacional de Saude Doutor Ricardo Jorge. In Spain, the study was approved by Comite dEtica de la Investigacion del Hospital Universitari Germans Trias i Pujol. In Italy, the study was approved by Comitato di Bioetica d' Ateneo, Universita degli studi di Torino. In Finland, waiver was obtained from Institutional Review Board of the Finnish Institute for Health and Welfare. In Switzerland, the study was approved by Gesundheits-, Sozial- und Integrationsdirektion Kantonale Ethikkommission fur die Forschung. In Lithuania, waiver was obtained from the Lithuanian Bioethics Committee. In Greece, the study was approved by Research Ethics Committee and University of West Attica. In Slovenia, the study was approved by Komisija Republike Slovenije za medicinsko etiko. In Croatia, the study was approved by Etiko povjerenstvo Hrvatskog zavoda za javno zdravstvo. In Estonia, the study was approved by Research Ethics Committee of the National Institute for Health Development. In Hungary, the study was approved by Health Science Council - Scientific and Research Ethics Committee Budapest. In Slovakia, the study was approved by Eticka komisia Univerzita Komenskeho v Bratislave Jesseniova lekarska fakulta v Martine. Further details are available from https://github.com/wongkerry/comix_preg/blob/main/ethics_committees.xlsx.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. ER -